RXDX News and Press, Prometheus Biosciences Inc. From 12/07/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: DANIEL CONSTANTE / Shutterstock Pinterest (NYSE: PINS ) stock is on the move Wednesday as investors react to an agreement with Elliott Investment Management L.P. According to a press release, this deal...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Prometheus Biosciences (NASDAQ: RXDX ) stock is rocketing higher on Wednesday after reporting results from its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies of PRA023. P...

Stock markets prepared to continue their downward trend on Wednesday, as early morning moves in futures markets indicated further declines after two losing sessions on Monday and Tuesday. The Nasdaq Composite (NASDAQINDEX: ^IXIC) looked poised to suffer the most significant declines, with...

Prometheus Biosciences ( NASDAQ: RXDX ) said its medicine PRA023 showed strong efficacy and favorable safety in two mid stage trials in patients with ulcerative colitis (UC) and Crohn's disease (CD). UC and CD are types of inflammatory bowel diseases. ART...

– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all ranked secondary endpoints –...

Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence .  The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Th...

Prometheus Biosciences press release ( NASDAQ: RXDX ): Q3 GAAP EPS of -$0.90 beats by $0.01 . Revenue of $0.97M (-4.0% Y/Y) beats by $0.39M . As of September 30, 2022, Prometheus had cash, cash equivalents and short-term investments of $260.2 million, compared ...

- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position provides runway into mid-2024 - SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIR...

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the...

Summary These articles are intended to provide readers with equity investment subjects [stocks, ETFs, REITs] which probably may experience rising market prices in next 3-5 months: Near-term expectations only. They are drawn from a 3,000+ equity population updated daily which infer...